Abstract: Various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.

Abstract: various side effects are reported for existing overactive bladder therapeutic drugs, and prophylactic or therapeutic agents for overactive bladder without side effects have been eagerly desired. The present invention provides a prophylactic or therapeutic agent for overactive bladder that comprises 5-aminolevulinic acids (ALAs) as the active ingredient.

Abstract: A monoclonal antibody to KIR2DS1 or a fragment containing an antigen-binding region thereof has VL having an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR1, having an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR2, and having an amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR3; and VH having an amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR1, having an amino acid sequence of SEQ ID NO

Abstract: A monoclonal antibody to KIR2DS1 or a fragment containing an antigen-binding region thereof has VL having an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR1, having an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR2, and having an amino acid sequence of SEQ ID NO: 3 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR3; and VH having an amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 5 or an amino acid sequence having the same amino acid sequence as the amino acid sequence except that one or several amino acids are conservatively substituted as CDR1, having an amino acid sequence of SEQ ID NO

Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (I): R1—NHCH2COCH2CH2COOR2??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.

Abstract: A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (1): R1—NHCH2COCH2CH2COOR2 ??(I) wherein R1 represents a hydrogen atom or an acyl group, and R2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group, or a salt thereof.